Immunodiagnostic Systems Hldgs PLC Launch of SARS-CoV-2 Antigen Rapid Tests (6864G)
27 Noviembre 2020 - 1:00AM
UK Regulatory
TIDMIDH
RNS Number : 6864G
Immunodiagnostic Systems Hldgs PLC
27 November 2020
Immunodiagnostic Systems Holdings plc.
27 November 2020
Launch of SARS-CoV-2 Antigen Rapid Tests
Immunodiagnostic Systems Holdings plc (IDS), a specialty
solution provider to the clinical laboratory diagnostic market,
announces that two SARS-CoV-2 Antigen Rapid Test kits are now
available for sale in the UK, European Union and other countries
which accept the CE mark as the basis of regulatory approval.
Both tests can be performed by a trained healthcare professional
in community locations (e.g. workplaces, schools, doctors'
surgeries) without the need for any laboratory equipment. These
tests determine the presence of the SARS-CoV-2 nucleocapsid protein
antigen using direct nasopharyngeal swab samples, providing a
result within 15 minutes.
Both fast and easy to use tests are based on the lateral flow
principle: one in a cassette format, one in a test card format.
These tests are provided by partners of IDS, and have been assessed
by the manufacturers as having the following performance
characteristics:
Specificity Sensitivity Time to Result
Lateral Flow
cassette 99.2% 96.7% 15 minutes
------------ ------------ ---------------
Lateral Flow
card 99.3% 92.0% 15 minutes
------------ ------------ ---------------
IDS now offers a comprehensive portfolio of SARS-CoV-2 antigen
and antibody tests for the laboratory as well as for community
locations; additional information of our SARS-CoV-2 assay portfolio
can be found on the IDS website at www.idsplc.com .
For further information:
Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 6111
Jaap Stuut, Chief Executive Officer
Paul Martin, Group Finance Director
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel
Oliver Jackson
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PRLBFBRTMTMTBFM
(END) Dow Jones Newswires
November 27, 2020 02:00 ET (07:00 GMT)
Immunodiagnostic Systems (LSE:IDH)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Immunodiagnostic Systems (LSE:IDH)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024